These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 14988745)

  • 41. Current Immunotherapies for Renal Cell Carcinoma.
    Al-Marrawi MY; Holder SL
    Curr Mol Pharmacol; 2016; 9(3):252-263. PubMed ID: 26177641
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adoptive cellular therapy.
    Hoffman DM; Gitlitz BJ; Belldegrun A; Figlin RA
    Semin Oncol; 2000 Apr; 27(2):221-33. PubMed ID: 10768601
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Are immunotherapy and chemotherapy in metastatic renal cell cancer out?].
    Schmitz-Dräger BJ
    Urologe A; 1992 Jul; 31(4):213-4. PubMed ID: 1514204
    [No Abstract]   [Full Text] [Related]  

  • 44. MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer.
    Wang Z; Liu Y; Zhang Y; Shang Y; Gao Q
    Oncotarget; 2016 Jan; 7(4):4760-9. PubMed ID: 26716894
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotherapy options in metastatic renal cell cancer: where we are and where we are going.
    Passalacqua R; Buti S; Tomasello G; Longarini R; Brighenti M; Dalla Chiesa M
    Expert Rev Anticancer Ther; 2006 Oct; 6(10):1459-72. PubMed ID: 17069530
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunotherapy for metastatic renal cell carcinoma.
    McDermott DF; Rini BI
    BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
    [No Abstract]   [Full Text] [Related]  

  • 48. Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma.
    Elsässer D; Stadick H; Stark S; Van de Winkel JG; Gramatzki M; Schrott KM; Valerius T; Schafhauser W
    Anticancer Res; 1999; 19(2C):1525-8. PubMed ID: 10365137
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
    Little B; Young M; Ho KJ
    Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel.
    Halbert RJ; Figlin RA; Atkins MB; Bernal M; Hutson TE; Uzzo RG; Bukowski RM; Khan KD; Wood CG; Dubois RW
    Cancer; 2006 Nov; 107(10):2375-83. PubMed ID: 17048248
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeted treatment for metastatic renal cell carcinoma and immune regulation.
    Laschos KA; Papazisis KT; Kontovinis LF; Kalaitzis C; Gianakopoulos S; Kortsaris AH; Touloupidis S
    J BUON; 2010; 15(2):235-40. PubMed ID: 20658715
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
    McDermott DF; Regan MM; Atkins MB
    Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Systemic treatment of renal-cell carcinoma--present status].
    Steiner T; Schubert J
    Dtsch Med Wochenschr; 2001 Sep; 126(39):1080-4. PubMed ID: 11602916
    [No Abstract]   [Full Text] [Related]  

  • 55. Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
    Rini BI
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1753-60. PubMed ID: 17181489
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma.
    Bex A; Horenblas S; de Gast GC
    Technol Cancer Res Treat; 2003 Jun; 2(3):205-10. PubMed ID: 12779351
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotherapy of metastatic renal cell carcinoma.
    McDermott DF
    Cancer; 2009 May; 115(10 Suppl):2298-305. PubMed ID: 19402060
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside.
    Weinstock M; McDermott DF
    Am Soc Clin Oncol Educ Book; 2015; ():e291-7. PubMed ID: 25993188
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Immunotherapy of renal cell carcinoma. With special emphasis on therapy of the elderly patient].
    Heinzer H; Huland E; Huland H
    Urologe A; 2003 Nov; 42(11):1450-2. PubMed ID: 14624342
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current management and future perspectives of metastatic renal cell carcinoma.
    Lee-Ying R; Lester R; Heng D
    Int J Urol; 2014 Sep; 21(9):847-55. PubMed ID: 24862210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.